Wilex finds US commercialisation partner for Rencarex


Munich/San Diego – German Wilex has sold the exclusive US marketing rights for RENCAREX® (girentuximab), its Phase III monoclonal antibody for adjuvant use in non-metastatic clear-cell renal cell cancer (ccRCC) to Prometheus Laboratories Inc. Under the terms of the agreement, Wilex will receive $19.0 million upfront, development fees, plus milestone payments and royalties on U.S. net sales of the chimeric monoclonal antibody that targets the CA IX-antigen, which is overexpressed on 95% of ccRCC and various other solid tumours. Additionally, Wilex has options for commercialisation outside the United States to one of Prometheus' marketed products or additional cash payments of up to $20 million. With the deal, the US company, which has a track record of commercialisation of oncology products, strengthens its oncology pipeline. girentuximab is currently being tested in a Phase III trial versus placebo in the adjuvant setting in 864 patients with non-metastatic clear cell renal cell cancer at high risk of recurrence after nephrectomy. WILEX expects the results from the interim analysis for efficacy of girentuximab in the second half of 2011, which could form the basis for the European MAA.



Berlin – German biotech associations have strengthened their collaboration. The Heidelberg-based European Association of Pharma Biotechnology (EAPB) and Germany’s Biotechnology Industry Organisation Bio Deutschland e. V. said...



European Biotechnology News wishes Merry Christmas and a Happy New Year! We will be back with daily news and a packed calendar on Monday 2nd January.



Berlin/Dortmund – German researchers have identified potential targets involved in the formation of so called neutrophil extracellular traps (NETs), DNA-protein nets that are formed by cells of the innate immune system to defend...



Heerlen/Leipzig – DSM Pharmaceutical Products, the custom manufacturing arm of Dutch Royal DSM NV, has licensed proprietary alcohol dehydrogenases from German enzyme specialist c-LEcta GmbH for enzyme screening programmes and...



Dresden/Munich/Bethesda – German and US researchers from NIH and the universities Munich and Dresden have developed the first mouse model ever that exactly mimics human key symptoms of psoriasis. The mice developed the same...



Göttingen/Paris – Researchers from Germany, Denmark and French BioAlliance Pharma S.A have found that reducing angiogenesis in xenotransplantation models of psoriasis and in mice with a disease that resembles psoriasis alleviates...



Regensburg – During the unravelling of a transcriptional network in photoreceptors, German and US researchers have identified a novel gene that affects the inherited retinal disease Retinitis pigmentosa (type 28). In a...

Displaying results 61 to 70 out of 454

< Previous 61-70 Next >

© 2007-2015 BIOCOM

Product of the week



All Events

Stock list

All quotes


  • FORMYCON13.90 EUR12.10%
  • MAGFORCE5.10 EUR7.82%
  • SANTHERA103.00 CHF5.64%


  • CYTOS0.32 CHF-17.95%
  • CO.DON2.15 EUR-4.44%
  • MEDIGENE3.80 EUR-4.28%


  • ADDEX3.44 CHF48.3%
  • CYTOS0.32 CHF39.1%
  • FORMYCON13.90 EUR37.9%


  • ACTELION100.70 CHF-13.3%
  • BIOFRONTERA2.02 EUR-12.2%
  • MOLOGEN5.72 EUR-9.9%


  • SANTHERA103.00 CHF2494.5%
  • BB BIOTECH248.45 EUR95.9%
  • FORMYCON13.90 EUR85.3%


  • CYTOS0.32 CHF-91.2%
  • MOLOGEN5.72 EUR-50.5%
  • 4SC0.82 EUR-50.0%

No liability assumed, Date: 28.01.2015

Current issue

All issues